LXRX•benzinga•
Lexicon Pharmaceuticals Announces Lancet Study Shows Sotagliflozin Reduces Cardiovascular Events In T2D Patients With CKD And High CV Risk, Meeting Primary Endpoint
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 18, 2025 by benzinga